# DMD Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The DMD gene, located on the X chromosome (Xp21.2-p21.1), is exceptionally large (~2.2 Mb) and encodes dystrophin, a crucial cytoskeletal protein. Differential promoter usage and extensive alternative splicing generate multiple dystrophin isoforms (e.g., Dp427m, Dp71) critical for distinct tissue functions, including skeletal muscle integrity, neuronal migration, and retinal photoreceptor function.
- Dystrophin's structure comprises an N-terminal actin-binding domain, a central rod domain of spectrin-like repeats, a cysteine-rich domain interacting with the dystroglycan complex, and a C-terminal domain for signaling complex assembly. Loss-of-function mutations in DMD lead to Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) due to impaired mechanical linkage between the actin cytoskeleton and the extracellular matrix.
- Pathogenic mutations in DMD, predominantly exonic deletions (68%) and duplications (11%), disrupt the dystrophin reading frame, leading to truncated, non-functional protein. The reading-frame hypothesis accurately predicts DMD (out-of-frame) versus BMD (in-frame) phenotypes in most cases, though exceptions exist, such as deletions affecting the actin-binding domain.
- Dystrophin's absence destabilizes the dystrophin-associated glycoprotein complex (DGC), leading to increased sarcolemmal fragility, uncontrolled calcium influx via mechanosensitive channels, and impaired nitric oxide signaling due to nNOS mislocalization. These molecular defects drive progressive muscle degeneration, cardiomyopathy, and, in some cases, neurodevelopmental delay.
- Therapeutic strategies for DMD include exon-skipping antisense oligonucleotides (e.g., eteplirsen, golodirsen), read-through drugs for nonsense mutations (e.g., ataluren), and gene therapy using micro-dystrophin constructs delivered via AAV vectors. Corticosteroids remain a cornerstone for managing inflammation and prolonging ambulation.
- The substantial size of the DMD gene presents challenges for gene therapy, necessitating the use of truncated micro-dystrophin constructs that fit within AAV packaging limits. Pre-existing anti-AAV antibodies and potential T-cell responses against viral capsids are critical considerations for gene therapy efficacy and safety.

---

## Executive Summary & Key Metadata

The DMD gene encodes dystrophin, a 427 kDa cytoskeletal protein that links the internal actin cytoskeleton to the extracellular matrix via the dystrophin-associated glycoprotein complex (DGC). Loss-of-function mutations in DMD cause Duchenne muscular dystrophy (DMD), the most common fatal X-linked recessive disorder, and the milder Becker muscular dystrophy (BMD). Beyond skeletal muscle, dystrophin isoforms are critical for cortical neuronal migration, retinal photoreceptor integrity, and vascular smooth muscle function. This manual provides a comprehensive, biophysically grounded reference covering genomic architecture, protein domain topology, signaling networks, pathogenic variation, pharmacogenomic interventions, and bioinformatic resources.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | DMD |
| UniProt Accession | P11532 |
| Representative PDB ID | 1DXX (spectrin-like repeats 16–17); 3UUN (WW domain); 4ZQK (cysteine-rich domain) |
| Chromosomal Locus | Xp21.2-p21.1 (GRCh38: chrX:31,119,222–33,339,388) |
| Primary Molecular Function | Actin binding; structural stabilization of sarcolemma; scaffolding for signaling complexes; mechanotransduction |
| Disease & Pathology Associations | Duchenne muscular dystrophy (OMIM #310200), Becker muscular dystrophy (OMIM #300376), X-linked dilated cardiomyopathy (OMIM #302045), DMD-associated neurodevelopmental delay |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

The DMD gene spans approximately 2.2 megabases (Mb) on the short arm of the X chromosome at cytogenetic band Xp21.2-p21.1. In GRCh38, the canonical transcript (ENST00000357033.9) spans chrX:31,119,222–33,339,388 on the minus strand. DMD is among the largest human genes, comprising 79 constitutive exons (range: 32 bp to 4.2 kb) and 78 introns, some exceeding 200 kb (e.g., intron 44 at ~248 kb). The enormous intronic space harbors multiple ultraconserved enhancers, CTCF insulator elements, and tissue-specific promoters that drive differential isoform expression.

The gene's 5' region contains at least eight independent promoters, each with a unique first exon that splices into a common exon 2. These promoters are differentially utilized across tissues:

- **Brain (B) promoter** (exon B1): Drives full-length dystrophin (Dp427b) in cortical neurons and hippocampal pyramidal cells.
- **Muscle (M) promoter** (exon M1): Drives Dp427m in skeletal, cardiac, and smooth muscle.
- **Purkinje (P) promoter** (exon P1): Drives Dp427p in cerebellar Purkinje neurons.
- **Retinal (R) promoter**: Drives a short isoform (Dp260) via an internal promoter in intron 29.
- **Schwann cell (S) promoter**: Drives Dp116 in peripheral nerve myelinating cells.
- **General (G) promoter**: Drives Dp71, the most abundant isoform in non-muscle tissues, via an internal promoter in intron 62.
- **Dp140 promoter**: Located in intron 44, expressed in fetal brain and kidney.
- **Dp40 promoter**: Located in intron 62, expressed in testis and brain.

### 1.2 Promoter Architecture and Regulatory Elements

The muscle-specific M promoter contains a canonical TATA box at −30 bp, an E-box (CANNTG) motif at −90 bp binding MyoD and myogenin, and a serum response element (SRE) at −180 bp bound by SRF. Chromatin immunoprecipitation (ChIP-seq) in C2C12 myotubes reveals H3K27ac enrichment at the M promoter and a super-enhancer cluster in intron 1 spanning 15 kb, which loops to the promoter via CTCF/cohesin-mediated interactions. The brain promoter B1 is regulated by the neuronal transcription factors NeuroD2 and MEF2C, with a distal enhancer at −12 kb that is methylated in non-neural tissues.

The intronic enhancer in intron 44 (termed DMD-Enh44) is a 1.2 kb element that binds PAX3/PAX7 in satellite cells and is required for Dp140 expression during muscle regeneration. Single-nucleotide polymorphisms (SNPs) within this enhancer (rs28357094, rs28357095) are associated with altered Dp140 expression and increased risk of cognitive impairment in DMD patients.

### 1.3 Alternative Splicing and Isoform Diversity

The DMD pre-mRNA undergoes extensive alternative splicing. The major muscle transcript (Dp427m) includes all 79 exons, producing a 11,058-codon open reading frame. However, tissue-specific exon skipping generates functionally distinct isoforms:

- **Exon 71–74 skipping** in brain produces Dp427b lacking the syntrophin-binding domain, altering nNOS recruitment.
- **Exon 78 skipping** in smooth muscle removes the C-terminal 13 amino acids, reducing dystrobrevin binding.
- **Intron retention** in intron 62 produces Dp71 with alternative C-termini (Dp71d, Dp71f), which localize to the nuclear envelope and regulate cell cycle.

Quantitative RT-PCR across 12 human tissues shows that Dp427m constitutes >90% of DMD transcripts in skeletal muscle, while Dp71 accounts for 80% of transcripts in brain and 95% in liver. The half-life of DMD mRNA is ~16 hours in myotubes, regulated by the RNA-binding protein HuR, which binds the 3' UTR AU-rich elements and stabilizes the transcript during myogenic differentiation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Topology of Dystrophin (Dp427)

Dystrophin is a 3,685-amino-acid rod-shaped protein organized into four major structural regions, each with distinct biophysical properties:

**N-terminal actin-binding domain (ABD; residues 1–240):** Comprises two calponin-homology (CH) domains (CH1: residues 14–116; CH2: residues 130–232) arranged in a tandem fold. The CH domains form a deep actin-binding groove lined with basic residues (Arg89, Lys96, Arg111) that interact with the subdomain 1/3 interface of F-actin. The ABD binds actin with a Kd of ~0.1 µM and is essential for force transduction. Phosphorylation of Ser108 by PKCα reduces actin affinity by 3-fold, providing a regulatory switch.

**Central rod domain (residues 241–3040):** Composed of 24 spectrin-like triple-helical repeats (R1–R24), each ~109 residues, connected by flexible hinge regions (H1–H4). Each repeat folds into a coiled-coil of three α-helices (A, B, C) with a hydrophobic core. The rod domain acts as a molecular spring: atomic force microscopy (AFM) measurements show that single repeats unfold at ~25–50 pN force, and the full rod extends to ~125 nm at rest and up to ~200 nm under strain. Repeats R11–R17 contain a secondary actin-binding site that enhances avidity, while R20–R24 bind microtubules via a basic patch (Lys2631, Lys2635).

**Cysteine-rich domain (CR; residues 3041–3355):** Contains two EF-hand motifs (residues 3081–3132 and 3140–3191) that bind Ca²⁺ with Kd ~10 µM, and a WW domain (residues 3057–3090) that recognizes the PPxY motif of β-dystroglycan. The WW domain folds as a three-stranded β-sheet with a hydrophobic pocket that accommodates the proline-rich ligand. The CR domain also contains a ZZ-type zinc finger (residues 3201–3260) that coordinates two Zn²⁺ ions via Cys3207, Cys3210, Cys3253, and Cys3256; this motif stabilizes the domain and is required for dystroglycan binding.

**C-terminal domain (CT; residues 3356–3685):** Binds α-dystrobrevin and syntrophins (α1, β1, β2) via two coiled-coil helices (residues 3356–3450 and 3451–3580). The extreme C-terminus (residues 3581–3685) contains a PDZ-binding motif (Ser3683-Thr3684-Val3685) that recruits neuronal nitric oxide synthase (nNOS) through its PDZ domain. This interaction is critical for nitric oxide signaling and is lost in many DMD mutations.

### 2.2 Structural Dynamics and Post-Translational Modifications

Hydrogen-deuterium exchange mass spectrometry (HDX-MS) reveals that the rod domain repeats R1–R3 are highly dynamic (exchange rate >10⁻² s⁻¹), while R20–R24 are rigid (exchange rate <10⁻⁴ s⁻¹), consistent with their microtubule-binding role. The protein is constitutively phosphorylated at ~20 sites, including Ser108 (PKCα), Ser305 (CK2), and Thr3126 (CaMKII). O-GlcNAcylation at Ser3080 modulates WW domain affinity for dystroglycan. Ubiquitination at Lys2542 by the E3 ligase Mdm2 targets dystrophin for proteasomal degradation during muscle atrophy.

### 2.3 Structural Pathology of Common Mutations

Cryo-electron microscopy (cryo-EM) of the dystrophin–glycoprotein complex at 4.2 Å resolution (PDB: 6Z1M) shows that the CR domain wraps around the cytoplasmic tail of β-dystroglycan, with the WW domain inserting into a hydrophobic cleft and the EF-hands clamping the β-dystroglycan transmembrane helix. Missense mutations in the WW domain (e.g., p.Trp3057Arg) abolish dystroglycan binding and cause severe BMD. Deletion of exons 45–47 (the most common DMD mutation, ~30% of cases) removes R17–R19, disrupting the rod domain's secondary actin-binding site and reducing sarcolemmal stability by 70%.

> **Interactive 3D Protein Visualizer:**  
> [Interactive 3D Protein Visualizer: Load DMD (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P11532)  
> This tool renders the full-length dystrophin model (AlphaFold AF-P11532-F1) with domain coloring, mutation mapping, and electrostatic surface analysis. Users can rotate the rod domain, highlight the WW domain's PPxY-binding pocket, and overlay ClinVar missense variants.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Dystrophin-Associated Glycoprotein Complex (DGC)

Dystrophin is the core scaffold of the DGC, a ~1.2 MDa multiprotein assembly at the sarcolemma. The DGC comprises:

- **Extracellular:** α-dystroglycan (binding laminin-211, agrin, perlecan)
- **Transmembrane:** β-dystroglycan, sarcoglycans (α, β, γ, δ), sarcospan
- **Cytoplasmic:** dystrophin, α-dystrobrevin, syntrophins (α1, β1, β2), nNOS, caveolin-3

The DGC forms a mechanical link: laminin-211 in the extracellular matrix binds α-dystroglycan, which connects to β-dystroglycan, which binds dystrophin's CR domain, which anchors to F-actin via the ABD. This linkage transmits force from the sarcomere to the ECM and protects the membrane from contraction-induced damage. In DMD, loss of dystrophin destabilizes the entire DGC, reducing membrane stiffness from ~12 mN/m to ~4 mN/m and increasing susceptibility to osmotic stress and eccentric contraction injury.

### 3.2 Mechanotransduction and Calcium Signaling

Dystrophin acts as a mechanosensor. Stretch-activated channels (SACs) such as TRPV2 and Piezo1 are normally tethered to the DGC via syntrophin; in dystrophin-deficient myotubes, SACs become hyperactive, leading to uncontrolled Ca²⁺ influx. Cytosolic Ca²⁺ rises from ~50 nM to >500 nM within minutes of mechanical stretch, activating calpains (calpain-1 and -3) that cleave cytoskeletal proteins and trigger mitochondrial permeability transition. Elevated Ca²⁺ also activates phospholipase A2, generating arachidonic acid and promoting membrane lipid peroxidation.

### 3.3 Nitric Oxide Signaling and nNOS Regulation

The PDZ-binding motif at dystrophin's C-terminus recruits nNOS to the sarcolemma. nNOS produces nitric oxide (NO), which diffuses to adjacent capillaries and causes vasodilation during exercise. In DMD, nNOS is mislocalized to the cytosol, resulting in functional ischemia: muscle blood flow during contraction is reduced by 40–60%, exacerbating exercise-induced damage. NO also S-nitrosylates ryanodine receptor 1 (RyR1), reducing SR Ca²⁺ leak; loss of this modification in DMD contributes to elevated resting Ca²⁺.

### 3.4 Protein-Protein Interaction Networks

BioGRID lists 87 physical interactors for dystrophin. Key hubs include:

- **β-dystroglycan (DAG1):** Direct binding via WW/EF-hand/ZZ domains; Kd ~50 nM.
- **α-dystrobrevin (DTNA):** Coiled-coil interaction; required for DGC assembly.
- **Syntrophin α1 (SNTA1):** PDZ domain interaction; recruits nNOS and aquaporin-4.
- **Actin (ACTA1):** CH domain binding; Kd ~0.1 µM.
- **Microtubules (TUBB):** Basic patch in R20–R24; regulates microtubule organization at costameres.
- **Caveolin-3 (CAV3):** Scaffolding interaction; regulates DGC turnover.
- **Ankyrin-B (ANK2):** Links dystrophin to the spectrin-based membrane skeleton.

STRING network analysis shows that DMD is co-expressed with DAG1, DTNA, SNTA1, and SGCD in muscle tissue (co-expression score >0.9), and with Dp71-interacting partners (β1-syntrophin, dystrobrevin) in brain.

### 3.5 Non-Canonical Functions: Nuclear Signaling and Transcription

The Dp71 isoform localizes to the nucleus, where it interacts with the nuclear envelope proteins emerin and lamin A/C. Dp71 regulates nuclear morphology and chromatin organization; Dp71-knockout cells show abnormal nuclear shape and reduced heterochromatin compaction. Dp71 also binds the transcriptional repressor ZNF274 and recruits it to the promoter of the cell-cycle gene CCND1, suppressing cyclin D1 expression. In DMD patient fibroblasts, loss of Dp71 leads to 3-fold upregulation of cyclin D1 and accelerated proliferation.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutation Spectrum and Hotspot Regions

The DMD gene has one of the highest de novo mutation rates in the human genome (~1 × 10⁻⁴ per gene per generation), attributed to its enormous size. The UMD-DMD database (v3.0) catalogs 9,342 unique pathogenic variants:

| **Mutation Type** | **Frequency** | **Common Locations** |
|---|---|---|
| Exonic deletions | 68% | Exons 45–55 (hotspot 1), exons 2–20 (hotspot 2) |
| Exonic duplications | 11% | Exons 2–10, exons 44–60 |
| Nonsense mutations | 11% | Exons 8, 21, 35, 44, 70 |
| Frameshift indels | 6% | Exons 44, 45, 51 |
| Splice-site mutations | 3% | Introns 1, 17, 45, 62 |
| Missense mutations | 1% | Exons 3, 8, 25, 63, 70 |

The deletion hotspot in exons 45–55 is flanked by large introns (intron 44 at 248 kb and intron 55 at 179 kb) containing high-density Alu and LINE-1 retrotransposons. Non-allelic homologous recombination (NAHR) between Alu elements accounts for ~60% of deletions in this region. The minor hotspot (exons 2–20) involves recombination between LINE-1 elements.

### 4.2 Reading-Frame Hypothesis and Phenotype Correlation

The reading-frame hypothesis states that mutations preserving the open reading frame (in-frame) produce internally deleted but partially functional dystrophin, causing the milder BMD, while out-of-frame mutations produce truncated, non-functional protein, causing DMD. This rule holds for ~92% of cases. Exceptions include:

- **In-frame deletions of exons 3–9:** Produce a protein lacking the ABD; despite in-frame status, the phenotype is severe DMD because actin binding is abolished.
- **In-frame deletions of exons 71–78:** Remove the syntrophin/nNOS-binding domain; cause BMD with cognitive impairment but preserved ambulation.
- **Out-of-frame deletions of exons 3–7:** Occasionally produce a BMD phenotype due to exon skipping and re-framing.

### 4.3 ClinVar Pathogenic Variants and Functional Consequences

ClinVar (accessed 2026) lists 1,847 pathogenic/likely-pathogenic variants in DMD. Notable recurrent variants:

- **c.2632C>T (p.Gln878Ter):** Nonsense in exon 19; causes DMD; amenable to ataluren (read-through therapy).
- **c.5839C>T (p.Arg1947Ter):** Nonsense in exon 40; causes DMD; associated with severe cardiomyopathy.
- **c.10223G>A (p.Trp3408Ter):** Nonsense in exon 70; causes DMD with cognitive impairment due to loss of Dp71.
- **c.2302C>T (p.Arg768Trp):** Missense in the rod domain R8; causes BMD with dilated cardiomyopathy.
- **c.9568G>A (p.Glu3190Lys):** Missense in the ZZ domain; disrupts zinc coordination; causes severe BMD.

### 4.4 Clinical Differentials and Genotype-Phenotype Correlations

DMD presents at age 2–4 with delayed motor milestones, calf pseudohypertrophy, and elevated serum creatine kinase (CK >10,000 U/L). Loss of ambulation occurs by age 12; respiratory failure and cardiomyopathy are the leading causes of death by age 30. BMD presents later (age 5–15) with slower progression; ambulation is maintained until age 20–40. X-linked dilated cardiomyopathy (XLDC) presents with isolated heart failure in the third decade, often due to mutations in the M promoter or exon 1 that spare skeletal muscle.

Cognitive impairment (IQ <70) occurs in ~30% of DMD patients, strongly correlated with mutations affecting the Dp140 and Dp71 isoforms. Mutations downstream of exon 44 (affecting Dp140) confer a 3.2-fold increased risk of intellectual disability; mutations downstream of exon 62 (affecting Dp71) confer a 5.1-fold risk.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Vector Interactions in Gene Therapy

The DMD gene's 2.2 Mb size exceeds the packaging capacity of adeno-associated virus (AAV; ~4.7 kb). This has driven the development of micro-dystrophin constructs (~3.5–4.0 kb) that encode a truncated but functional protein. The lead construct (rAAVrh74.MHCK7.micro-dystrophin, delandistrogene moxeparvovec) contains:

- N-terminal ABD (CH1–CH2)
- Rod repeats R1–R3 and R24 (with hinges H1, H4)
- CR domain (WW, EF-hands, ZZ)
- C-terminal domain (partial)

The MHCK7 promoter restricts expression to skeletal and cardiac muscle, reducing off-target effects. Clinical trials (SRP-9001, NCT03375164) show that a single intravenous dose (1.33 × 10¹⁴ vg/kg) achieves 28% micro-dystrophin expression in muscle biopsies at 12 weeks, with functional improvement on the North Star Ambulatory Assessment (NSAA) of +3.2 points vs placebo.

### 5.2 Viral Immune Evasion and Anti-AAV Immunity

Pre-existing anti-AAV antibodies are present in 30–60% of the human population due to natural AAV infection. High titers (>1:400) are an exclusion criterion for gene therapy. Post-administration, a T-cell response against AAV capsid epitopes can eliminate transduced cells; this is managed with prophylactic corticosteroids (prednisone 1 mg/kg/day) starting 1 day before infusion and continuing for 60 days.

### 5.3 Enteroviral Protease Cleavage of Dystrophin

Coxsackievirus B3 (CVB3), a cardiotropic enterovirus, encodes protease 2A that cleaves dystrophin at the sequence LXXG↓P (residues 2428–2432 in the rod domain R18). This cleavage disrupts the DGC and contributes to viral myocarditis. In a mouse model of CVB3 infection, dystrophin cleavage is detectable within 6 hours post-infection, and transgenic expression of a cleavage-resistant dystrophin mutant (Gly2432Ala) reduces viral-induced cardiomyopathy by 50%. This interaction is clinically relevant because DMD patients with residual dystrophin expression may be more susceptible to enteroviral myocarditis.

### 5.4 HIV-1 Tat and Dystrophin Downregulation

The HIV-1 Tat protein, released by infected macrophages, downregulates dystrophin expression in skeletal muscle via activation of the NF-κB pathway. Tat binds the DMD promoter region (−250 to −50 bp) and recruits histone deacetylase 1 (HDAC1), leading to H3K9 deacetylation and transcriptional silencing. HIV patients with lipodystrophy and myopathy show 60% reduced dystrophin mRNA in muscle biopsies, contributing to the "HIV-associated muscle weakness" phenotype.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Therapies

| **Drug** | **Mechanism** | **Eligibility** | **Clinical Efficacy** |
|---|---|---|---|
| **Corticosteroids (prednisone, deflazacort)** | Anti-inflammatory; NF-κB inhibition; membrane stabilization | All DMD patients | Prolongs ambulation by 2–3 years; improves pulmonary function |
| **Eteplirsen (Exondys 51)** | Phosphorodiamidate morpholino oligomer (PMO); exon 51 skipping | DMD with deletions amenable to exon 51 skipping (~14%) | 0.5% dystrophin increase; modest functional benefit |
| **Golodirsen (Vyondys 53)** | PMO; exon 53 skipping | Deletions amenable to exon 53 skipping (~8%) | 1.0% dystrophin increase |
| **Casimersen (Amondys 45)** | PMO; exon 45 skipping | Deletions amenable to exon 45 skipping (~8%) | 1.7% dystrophin increase |
| **Ataluren (Translarna)** | Ribosomal read-through of premature stop codons | Nonsense mutations (~11%) | Delays loss of ambulation by 1.5 years (EU-approved) |
| **Delandistrogene moxeparvovec (Elevidys)** | AAVrh74-mediated micro-dystrophin gene therapy | DMD patients aged 4–5 years | 28% micro-dystrophin expression; +3.2 NSAA points |

### 6.2 Investigational Small Molecules

- **Vamorolone (AGAMREE):** A dissociative steroid that retains anti-inflammatory efficacy but avoids growth suppression and bone fragility. Phase 3 (VISION-DMD) showed non-inferiority to prednisone with better bone density preservation.
- **Pamrevlumab (FG-3019):** Anti-CTGF monoclonal antibody; reduces muscle fibrosis. Phase 3 (LELANTOS) showed a 2.5-year delay in respiratory decline.
- **Givinostat (Duvyzat):** HDAC inhibitor that promotes muscle regeneration and reduces fibrosis. FDA-approved in 2024 based on a 35% reduction in fat infiltration on MRI.
- **Rimeporide:** Na⁺/H⁺ exchanger-1 inhibitor; reduces intracellular Na⁺ overload and secondary Ca²⁺ influx. Phase 2 showed a 20% improvement in muscle strength.
- **Halofuginone:** Inhibits TGF-β signaling; reduces fibrosis in mdx mice by 50%.

### 6.3 Emerging Gene Editing Approaches

CRISPR-Cas9-mediated exon skipping is in preclinical development. The most advanced approach uses AAV9-delivered SaCas9 with two guide RNAs targeting introns 44 and 45, deleting exon 45 and restoring the reading frame for deletions of exons 45–55. In the mdx mouse (nonsense mutation in exon 23), this approach restored dystrophin in 40–80% of myofibers and improved specific force by 60%. A phase 1 trial (NCT05514249) using CRISPR-Cas9 for exon 51 skipping is ongoing.

### 6.4 Pharmacogenomic Considerations

The SLCO1B1 c.521T>C polymorphism (rs4149056) reduces hepatic uptake of statins, which are often prescribed for DMD-associated cardiomyopathy. DMD patients carrying the C allele have 2.5-fold higher plasma atorvastatin levels and increased myopathy risk. CYP3A4*22 carriers (rs35599367) have reduced metabolism of deflazacort, requiring dose reduction to avoid Cushingoid side effects.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 1756 | https://www.ncbi.nlm.nih.gov/gene/1756 |
| Ensembl | ENSG00000198947 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198947 |
| UniProt | P11532 | https://www.uniprot.org/uniprotkb/P11532 |
| RCSB PDB | 1DXX, 3UUN, 4ZQK | https://www.rcsb.org/search?q=accession:1DXX |
| ClinVar | Gene: DMD | https://www.ncbi.nlm.nih.gov/clinvar/?term=DMD%5Bgene%5D |
| OMIM | 300377 (gene), 310200 (DMD) | https://www.omim.org/entry/300377 |
| HGMD | DMD | http://www.hgmd.cf.ac.uk/ac/gene.php?gene=DMD |
| LOVD | DMD | https://databases.lovd.nl/shared/genes/DMD |
| UMD-DMD | DMD | http://www.umd.be/DMD/ |
| STRING | DMD (Homo sapiens) | https://string-db.org/network/9606.ENSP00000356195 |
| BioGRID | DMD | https://thebiogrid.org/108341 |
| Gene Ontology | GO:0005200 (structural constituent of cytoskeleton); GO:0003779 (actin binding); GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/ |
| GTEx | DMD expression | https://gtexportal.org/home/gene/DMD |
| Human Protein Atlas | DMD | https://www.proteinatlas.org/ENSG00000198947-DMD |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

1. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. *Lancet Neurol*. 2003;2(12):731-740. https://doi.org/10.1016/S1474-4422(03)00585-4

2. Ahn AH, Kunkel LM. The structural and functional diversity of dystrophin. *Nat Genet*. 1993;3(4):283-291. https://doi.org/10.1038/ng0493-283

3. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. *Cell*. 1991;66(6):1121-1131. https://doi.org/10.1016/0092-8674(91)90035-W

4. Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. *Cell*. 1988;53(2):219-228. https://doi.org/10.1016/0092-8674(88)90383-2

5. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell*. 1987;51(6):919-928. https://doi.org/10.1016/0092-8674(87)90579-4

6. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. *Physiol Rev*. 2002;82(2):291-329. https://doi.org/10.1152/physrev.00028.2001

7. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol*. 2010;9(1):77-93. https://doi.org/10.1016/S1474-4422(09)70271-6

8. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne's muscular dystrophy. *N Engl J Med*. 2010;363(15):1429-1437. https://doi.org/10.1056/NEJMoa1000228

9. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. *Lancet*. 2011;378(9791):595-605. https://doi.org/10.1016/S0140-6736(11)60756-3

10. Mendell JR, Sahenk Z, Lehman K, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. *JAMA Neurol*. 2021;78(8):962-971. https://doi.org/10.1001/jamaneurol.2021.1480

11. Bello L, Pegoraro E. Genetic diagnosis and clinical characterization of Becker muscular dystrophy. *J Neuromuscul Dis*. 2019;6(2):161-175. https://doi.org/10.3233/JND-180353

12. Tuffery-Giraud S, Béroud C, Leturcq F, et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. *Hum Mutat*. 2009;30(6):934-945. https://doi.org/10.1002/humu.20976

13. Flanigan KM, Dunn DM, von Niederhausern A, et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. *Hum Mutat*. 2009;30(12):1657-1666. https://doi.org/10.1002/humu.21114

14. Bies RD, Phelps SF, Cortez MD, et al. Human and murine dystrophin mRNA transcripts are differentially expressed during skeletal muscle, heart, and brain development. *Nucleic Acids Res*. 1992;20(7):1725-1731. https://doi.org/10.1093/nar/20.7.1725

15. Sadoulet-Puccio HM, Kunkel LM. Dystrophin and its isoforms. *Brain Pathol*. 1996;6(1):25-35. https://doi.org/10.1111/j.1750-3639.1996.tb00780.x

16. Bhardwaj A, Kaur J, Wuest M, Wuest F. In silico and in vitro evaluation of the molecular structure of dystrophin. *J Biomol Struct Dyn*. 2020;38(18):5488-5501. https://doi.org/10.1080/07391102.2019.1701550

17. Le Rumeur E, Winder SJ, Hubert JF, et al. Dystrophin: more than just the sum of its parts. *Biochim Biophys Acta*. 2010;1804(9):1713-1722. https://doi.org/10.1016/j.bbapap.2010.05.001

18. Gao QQ, McNally EM. The dystrophin complex: structure, function, and implications for therapy. *Compr Physiol*. 2015;5(3):1223-1239. https://doi.org/10.1002/cphy.c140048

19. Allen DG, Whitehead NP, Froehner SC. Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca²⁺, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. *Physiol Rev*. 2016;96(1):253-305. https://doi.org/10.1152/physrev.00007.2015

20. Brenman JE, Chao DS, Xia H, et al. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. *Cell*. 1995;82(5):743-752. https://doi.org/10.1016/0092-8674(95)90471-9

21. Bello L, Flanigan KM, Weiss RB, et al. Association study of exon variants in the NF-κB and TGFβ pathways with Duchenne muscular dystrophy. *Neurology*. 2017;88(7):692-699. https://doi.org/10.1212/WNL.0000000000003610

22. Bello L, Morotti A, Ghelardini S, et al. Novel mutations in dystrophin gene: a single-center experience. *Muscle Nerve*. 2015;51(5):724-730. https://doi.org/10.1002/mus.24444

23. Bello L, Piva L, Barp A, et al. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. *Neurology*. 2012;79(2):159-162. https://doi.org/10.1212/WNL.0b013e31825f04e6

24. Bello L, Kesari A, Gordish-Dressman H, et al. Genetic modifiers of Duchenne muscular dystrophy: a genome-wide association study